TABLE 2.

Antimicrobial activity of Defr1 against a spectrum of gram-positive and gram-negative organisms and a fungus

Organism and straina	Description or origin	MBC (μg/ml)b
		Pol	Defr1	Defr1 Y5C	Defr1-1cys
					Oxidized	Reduced
Gram-negative bacteria
P. aeruginosa
PAO1	Reference strain	0.5	6	50	6	>50
C3425	Manchester	1	6	50
H183	Liverpool	1	6	100
C4269	Brisbane	1	6	>100
C3781	Melbourne	0.5	6	100
E. coli
ATCC 25922	Reference strain	0.25	8	>100	12	>50
B. cepacia
ATCC 25416	Type strain	>512	>100	>100
B. cenocepacia
ATCC BAA-245	Type strain	>512	>100	>100	>100	>100
S. maltophilia
C1980	Clinical isolate	32	12.5	>100
C3625	Clinical isolate	32	6	>100
C3626	Clinical isolate	32	3	>100
C3627	Clinical isolate	64	6	>100
B. bronchiseptica
J3083	Reference strain	0.12	6	>100
R. pickettii
R4050/C3079	Reference strain	>512	3	>100
R. eutropha
ATCC 17697	Reference strain	128	3	>100
A. baumannii
ATCC 19606	Type strain	1	3	12.5	6	>50
Gram-positive bacteria
E. faecalis ATCC 700802	Reference strain	256	6	100	12	>50
S. aureus ATCC 25923	Reference strain	256	10	>100	12	>50
S. aureus J2918-MRSAc	Clinical isolate	64	6	>100
Fungus
C. albicans J2922	Clinical isolate	>512	3	25

^aResistance phenotypes of clinical isolates for ciprofloxacin (Cip), meropenem (Mer), tobramycin (Tob) colistin (Col), and methicillin (Met): strain C3425, Mer resistant [Mer-R], Col-R; H183, Tob-R; C4269, Tob-R; C3781, Mer-R, Tob-R; C1980, Cip-R, Mer-R, Tob-R; C3625, Cip-R, Mer-R, Col-R; C3626, Cip-R, Mer-R; C3627, Mer-R, Tob-R; J2918, Cip-R, Met-R.

^bValues represent the MBCs for oxidized Defr1, Defr1 Y5C, and polymyxin (Pol) as a control. MBC data for Defr1 and Y5C against PAO1, E. coli ATCC 25922, S. aureus ATCC 25923, E. faecalis ATCC 292126, and C. albicans J2922 have been previously reported (3) and are repeated here as comparators.

^cMRSA, methicillin-resistant Staphylococcus aureus.